Kuros Biosciences Ltd. (CH:KURN)
:KURN
Top Page
Kuros Biosciences
(KURN)
Select Model
Select Model
Rating:56Neutral
Price Target:
CHF23.00
▼(-18.32% Downside)
Action:ReiteratedDate:03/13/26
The score is primarily supported by strong operating progress (rapid revenue growth, high gross margins, and a 2025 profitability inflection) and a low-leverage balance sheet. It is held back by deteriorating 2025 cash flow (negative operating and free cash flow), a weak trend versus moving averages, and a very elevated P/E multiple.
Positive Factors
Revenue Growth & Scale
Rapid, multi-year revenue scaling indicates durable commercial traction and broader market adoption of core products. A much larger revenue base supports investment in sales, distribution and manufacturing, enables operating leverage, and reduces execution risk tied to early-stage commercialization.
Negative Factors
Weak Cash Conversion
Despite GAAP profitability in 2025, negative operating and free cash flow signal working-capital or investment drains that can undermine internal funding. If this cash conversion weakness persists it raises near-term funding sensitivity and increases the likelihood of dilutive financing or constrained growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Scale
Rapid, multi-year revenue scaling indicates durable commercial traction and broader market adoption of core products. A much larger revenue base supports investment in sales, distribution and manufacturing, enables operating leverage, and reduces execution risk tied to early-stage commercialization.
Read all positive factors
Kuros Biosciences (KURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF856.46M
Dividend YieldN/A
Average Volume (3M)128.87K
Price to Earnings (P/E)498.6
Beta (1Y)1.38
Revenue Growth104.01%
EPS Growth33.25%
CountryCH
Employees122
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.09
Shares Outstanding39,179,276
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF38.00Price Target Upside34.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.4
Revenue Forecast (FY)CHF227.92M
Kuros Biosciences Business Overview & Revenue Model
Company Description
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates th...
How the Company Makes Money
Kuros makes money primarily by selling bone graft substitute products (notably the MagnetOs portfolio) that are used by surgeons and hospitals in spine, orthopedic, and related bone-fusion procedures. Revenue is generated from per-unit product sal...
Kuros Biosciences Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 121.30M | 75.56M | 33.56M | 17.99M | 13.81M |
| Gross Profit | 104.79M | 62.03M | 23.94M | 10.77M | 10.07M |
| EBITDA | 10.13M | -561.00K | -6.84M | -8.84M | -5.29M |
| Net Income | 2.12M | -3.72M | -13.73M | -14.60M | -7.54M |
Balance Sheet | |||||
| Total Assets | 107.21M | 84.54M | 71.46M | 82.95M | 91.34M |
| Cash, Cash Equivalents and Short-Term Investments | 15.66M | 17.46M | 14.21M | 24.07M | 28.62M |
| Total Debt | 3.94M | 1.79M | 2.14M | 1.91M | 8.93M |
| Total Liabilities | 40.28M | 25.79M | 14.75M | 14.09M | 14.36M |
| Stockholders Equity | 66.93M | 58.75M | 56.71M | 68.86M | 76.98M |
Cash Flow | |||||
| Free Cash Flow | -2.40M | 2.03M | -9.17M | -7.75M | -5.83M |
| Operating Cash Flow | -377.87K | 3.14M | -8.84M | -7.35M | -5.45M |
| Investing Cash Flow | -2.03M | -1.11M | -326.00K | -400.00K | -374.00K |
| Financing Cash Flow | 1.17M | 1.34M | -171.00K | 3.22M | 6.08M |
Kuros Biosciences Technical Analysis
Negative
28.16
Price Trends
25.73
Negative
27.06
Negative
27.14
Negative
Market Momentum
-1.07
Positive
34.99
Neutral
10.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Negative. The current price of 28.16 is above the 20-day moving average (MA) of 25.14, above the 50-day MA of 25.73, and above the 200-day MA of 27.14, indicating a bearish trend. The MACD of -1.07 indicates Positive momentum. The RSI at 34.99 is Neutral, neither overbought nor oversold. The STOCH value of 10.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:KURN.
Kuros Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF640.82M | 16.63 | ― | ― | 58.51% | ― | |
56 Neutral | CHF856.46M | 498.59 | -7.82% | ― | 104.01% | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF308.17M | -38.37 | ― | ― | 744.64% | ― | |
48 Neutral | CHF213.03M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF131.02M | -2.05 | -51.05% | ― | -100.00% | 14.45% | |
45 Neutral | CHF770.58M | -8.17 | ― | ― | 229.23% | 63.47% |
* Healthcare Sector Average
CH:KURN
Kuros Biosciences
21.86
2.72
14.21%
CH:MOLN
Molecular Partners AG
3.25
-0.49
-13.12%
CH:BSLN
Basilea Pharmaceutica
52.50
6.00
12.90%
CH:IDIA
Idorsia Ltd
3.09
2.05
197.97%
CH:NWRN
Newron Pharmaceuticals SpA
14.82
6.84
85.71%
CH:SANN
Santhera Pharmaceuticals Holding
15.18
0.28
1.88%
Kuros Biosciences Corporate Events
Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion
Mar 10, 2026
Kuros Biosciences reported a 72% jump in 2025 medical device sales to USD 146.1 million, driven almost entirely by a 71% surge in direct MagnetOs bone graft revenue to USD 143.9 million. Adjusted EBITDA rose to USD 19.6 million with a 13.4% margin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.